CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM041490
035-os BibID:(Wos)000251331300008 (Scopus)36349018414
Első szerző:Brugós László (tüdőgyógyász, klinikai immunológus, allergológus)
Cím:Modulation of adenosine-induced response in the guinea pig trachea duirng long-term caffeine treatment : possible role of epthelium / László Brugós, Rudolf Gesztelyi, Judit Zsuga, Ágnes Cseppentő, Ilona Benkő, Zoltán Galajda, György Deák, Sándor Sipka, Tamás Rőszer, Péter Kovács, Mária Szilasi, István Édes, András József Szentmiklósi
Dátum:2007
ISSN:1347-8613
Megjegyzések:The responses to adenosine were studied on isolated, methacholine-precontracted tracheal strips of guinea pigs in the course of long-term caffeine or solvent treatment. Guinea pigs were fed caffeine for 10 weeks (average serum caffeine concentration: 39.1 ± 3.9 ?M). In epithelium-intact tracheal preparations (EITPs), sensititization to adenosine-induced relaxation (AIR) developed. It attained a maximum in week 1 of caffeine treatment, and then its level diminished and disappeared completely by weeks 4 - 6. In epithelium-denuded tracheal preparations (EDTPs), an increase in the sensitivity to adenosine was observed from week 1 to week 10 (a 4 - 6-fold reduction in EC50). Use of a coaxial bioassay system confirmed the role of epithelium in this process. The enhancement of the AIR of the EITPs was not modified by inhibitors of cyclooxygenase and lipoxygenase. Following depletion of the neuropeptides by acute capsaicin pretreatment, the AIR of the EITPs was strongly enhanced after caffeine treatment for 6 weeks. In chronically caffeine-treated EITPs, the inhibition of neutral endopeptidase led to dramatic reduction of the AIR. On the basis of the results by inhibiting nitric oxide synthase, it can be supposed that nitric oxide released from EITPs of long-lasting caffeine-treated animals operated as a constrictor agent. Our results show that chronic caffeine treatment gives rise to an initial sensitization to adenosine of the EITPs, this being followed by the development of a specific adaptive process in the epithelial cells, which counterbalances the increased tracheal sensitivity to adenosine.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Journal Of Pharmacological Sciences. - 105 : 3 (2007), p. 279-290. -
További szerzők:Gesztelyi Rudolf (1969-) (kísérletes farmakológus) Zsuga Judit (1973-) (neurológus, pszichoterapeuta, egészségügyi szakmanager) Cseppentő Ágnes (1953-) (orvos) Benkő Ilona (1954-) (orvos, farmakológus) Galajda Zoltán (1962-) (szívsebész, érsebész) Deák György (1954-) (polimer kémikus) Sipka Sándor (1945-) (laboratóriumi szakorvos) Röszer Tamás (1979-) (orvos, biológus) Kovács Péter (1939-) (farmakológus) Szilasi Mária (1953-) (tüdőgyógyász, klinikai immunológus, allergológus, belgyógyász) Édes István (1952-) (kardiológus) Szentmiklósi József András (1948-) (farmakológus, klinikai laboratóriumi szakorvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM020272
Első szerző:Djazayeri, Katayoun
Cím:Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil / Katayoun Djazayeria, Zoltán Szilvássy, Klára Benkő, Bernadett Rózsa, Boglárka Szabó, A. József Szentmiklósi, Ilona Benkő
Dátum:2006
ISSN:1043-6618
Megjegyzések:AbstractHaematopoietic colony-stimulating factors are used frequently to moderate myelotoxicity, but administration of granulocyte-colony-stimulating factor (G-CSF) prior to chemotherapy actually may worsen the toxic effects on bone marrow. This is important in the design of clinical cancer treatment protocols. Previously, we found that rosiglitazone may protect granulocyte-macrophage progenitor cells (CFU-GM) against damage caused by a single dose of 5-fluorouracil (5-FU). Our new studies are designed to evaluate whether rosiglitazone has similar beneficial effects on bone marrow preservation when administered concurrently with repeated, daily doses of 5-FU while restricting regeneration time. Myelotoxicity characterized by the decrease in cellularity, frequency of granulocyte-macrophage progenitor cells and CFU-GM content of femoral bone marrow in mice. Five-day oral rosiglitazone pre-treatment decreased the susceptibility of granulocyte-macrophage progenitors to 5-FU damage. Significantly, more CFU-GM cells survived after the single intraperitoneal dose of 5-FU (100 mg kg(-1)). The increased frequency of CFU-GM cells with their intensive proliferation allowed faster restoration of the damaged CFU-GM compartment than was seen in the case of repeated daily administration of the cytostatic drug (25 or 50 mg kg(-1)) together with rosiglitazone for 7 consecutive days. The expansion of the CFU-GM compartment was 3 times and 50 times greater in the combined-treated mice than in their counterparts treated with repeated doses of 5-FU alone, although differences in absolute neutrophil counts were not significant. In conclusion, our results indicated that rosiglitazone has protective effects on bone marrow progenitor cells even after daily 5-FU treatment but further studies are warranted to evaluate the optimal treatment schedules.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
rosiglitazone
myelotoxicity
5-fluorouracil
Megjelenés:Pharmacological Research. - 53 : 2 (2006), p. 156-161. -
További szerzők:Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Benkő Klára Rózsa Bernadett (1981-) (molekuláris biológus) Szabó Boglárka Szentmiklósi József András (1948-) (farmakológus, klinikai laboratóriumi szakorvos) Benkő Ilona (1954-) (orvos, farmakológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1